Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines

Table 4 Burdens, harms, benefits, and efficiencies at 2-year adherence rates for fecal immunological technique/fecal occult blood testing compared to recommended intervals for colonoscopy and mt-sDNA, ages 50-75, per 1000 people screened

		Burdens and harms			Benefits
CISNETmodel	Test	Stool tests	Total COL	Complications	LYG	CRC DA	CRC incidence reduction	CRC mortality reduction	% of COL 10y LYG	COL per LYG	Complications per LYG	Complications per DA
SimCRC	COL 10y	0	4007	14	275	24	81%	87%	100%	15	0.051	0.58
	FIT2y	9326	1215	7	234	20	53%	72%	85%	5	0.030	0.35
	hsFOBT2y	8388	1597	9	235	21	56%	73%	86%	7	0.038	0.43
	mt-sDNA3y	5990	1701	9	250	22	63%	78%	91%	7	0.036	0.41
MISCAN	COL 10y	0	4101	15	248	22	62%	79%	100%	17	0.060	0.68
	FIT2y	9342	1243	8	200	17	35%	62%	81%	6	0.040	0.47
	hsFOBT2y	8408	1636	9	200	18	37%	63%	81%	8	0.045	0.50
	mt-sDNA3y	5779	1714	9	215	19	43%	68%	87%	8	0.042	0.47
CRC-SPIN	COL 10y	0	4049	15	270	24	88%	90%	100%	15	0.056	0.62
	FIT2y	9241	1346	9	207	18	58%	68%	77%	6	0.043	0.50
	hsFOBT2y	8448	1626	9	212	19	62%	70%	78%	8	0.042	0.47
	mt-sDNA3y	5927	1827	10	226	20	68%	76%	84%	8	0.044	0.50

CISNET: National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network; CRC: Colorectal cancer; SimCRC: Simulation model of CRC; MISCAN: Microsimulation screening analysis; CRC-SPIN: Colorectal cancer simulated population model for incidence and natural history; COL: Colonoscopies; LYG: Life-years gained; DA: Deaths averted; COL 10y: Colonoscopy at a 10-year interval; FIT: Fecal immunological test.